The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239

Cytochrome P450 (CYP) 3A4 is an enzyme involved in the metabolism of many drugs that are currently on the market and is therefore a key player in drug–drug interactions (DDIs). ACT‐1004‐1239 is a potent and selective, first‐in‐class ACKR3/CXRC7 antagonist being developed as a treatment for demyelina...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical and translational science Vol. 17; no. 7; pp. e13883 - n/a
Main Authors:	Huynh, Christine, Dingemanse, Jasper, Meyer zu Schwabedissen, Henriette E., Fonseca, Marlene, Sidharta, Patricia N.
Format:	Journal Article
Language:	English
Published:	United States John Wiley & Sons, Inc 01.07.2024 John Wiley and Sons Inc Wiley
Subjects:	Adult Antifungal agents Area Under Curve Blood pressure Chemokines Cytochrome Cytochrome P-450 CYP3A - metabolism Cytochrome P-450 CYP3A Inhibitors - administration & dosage Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Cytochrome P-450 CYP3A Inhibitors - pharmacology Cytochrome P450 Demyelinating diseases Demyelination Drug dosages Drug interaction Drug Interactions Drug metabolism Enzymes Healthy Volunteers Humans Itraconazole Itraconazole - administration & dosage Itraconazole - pharmacokinetics Itraconazole - pharmacology Ligands Male Metabolism Metabolites Middle Aged Multiple sclerosis Pharmaceuticals Pharmacokinetics Young Adult Portugal
ISSN:	1752-8054, 1752-8062, 1752-8062
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!